COTI’s strategy is to partner with pharmaceutical, biotechnology and therapeutics companies at an early stage to augment their pipelines and accelerate innovation. COTI can add value to our partners through two distinct partnering opportunities:
- Lead Discovery Collaborations
- Out-Licensing
COTI has a flexible approach to deal making and is interested in partnerships that allow for sharing both risk and reward. COTI currently has research programs targeting a number of different cancer indications and molecular targets that are believed to assist in eradicating cancer, Multiple Sclerosis, Alzheimer’s disease, and HIV. COTI is also well positioned to discover drug candidates for many other CNS and cancer indications to assist partners in bringing novel drugs to market in an accelerated fashion.
Current partnerships include:
- MD Anderson Cancer Center, University of Texas, Houston
- Western University, London, Canada
- Delmar Chemicals, Montreal, Canada
